Aflac Incorporated

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

UBS Trims Aflac (AFL) Target, Sees “Limited Wiggle-Room” in Current Environment

AI-generated analysis

📉 UBS lowered its price target on Aflac Inc. (NYSE:AFL) from $116 to $114, maintaining a Neutral rating.

⚠️ The analyst firm noted "relatively limited wiggle-room" for disability margins due to cyclicality and economic uncertainty.

📅 UBS updated its earnings estimate timeline by rolling forward the target from 2026 estimates to 2027 figures.

🌍 Japan's underlying earned premiums are expected to decline between 1% and 2% during the Q4 2025 earnings call.

📊 For Japan, the expense ratio is projected to range from 20% to 23%, with a benefit ratio of 60% to 63%.

🇺🇸 US net earned premium growth remains expected at the lower end of the 3% to 6% range.

💵 The US benefit ratio is projected between 48% and 52%, while the expense ratio ranges from 36% to 39%.

💼 Aflac provides financial protection through subsidiaries in both the United States and Japan.

🏥 The company's core business focuses on supplemental health and life insurance products.

🤖 The article suggests certain AI stocks offer greater upside potential compared to AFL.

⚖️ UBS highlights that AI stocks carry less downside risk than current investments in Aflac.

📊 Readers are directed to a free report on short-term AI stocks benefiting from onshoring trends and tariffs.

🏆 Aflac is listed among the 15 Best Cheap Dividend Stocks to Buy according to another source mentioned.

📰 Additional reading points include blue chip stocks with highest dividends and bank stocks with highest dividends.

Bullish Signals
  • Aflac Incorporated is included among the 15 Best Cheap Dividend Stocks to Buy, indicating its attractive valuation and yield potential.
  • Max Broden, Senior EVP & CFO, confirmed that most of the company's 2026 guidance remains in place despite adjustments, providing stability for investors.
  • For the US business, net earned premium growth is still expected at the lower end of the 3% to 6% range, demonstrating continued market expansion.
  • The core business focuses on supplemental health and life insurance products with subsidiaries in both the United States and Japan, offering diversified geographic exposure.
Risk Factors
  • UBS lowered its price target on Aflac from $116 to $114, signaling reduced analyst confidence in the stock's near-term value.
  • The firm maintains a Neutral rating and notes there is 'relatively limited wiggle-room' for disability margins due to cyclicality and economic uncertainty.
  • Aflac faces potential headwinds with underlying earned premiums expected to decline by 1% to 2% in its Japan operations during 2026.
  • Despite continued expansion of newer business lines, the US expense ratio is projected to increase to between 36% and 39%.
  • Analysts argue that certain AI stocks offer greater upside potential and carry less downside risk compared to Aflac's traditional insurance model.
  • The company continues to face scrutiny as investors may prefer high-growth AI exposure over the limited growth profile of an established insurer like Aflac.
Full Analysis
UBS has downgraded its price target for Aflac Incorporated (NYSE:AFL) to $114 from $116 while maintaining a Neutral rating, citing concerns about the current economic landscape. The bank's analysts highlighted "relatively limited wiggle-room" for disability margins due to cyclicality and economic uncertainty, leading them to roll their forecast period forward from 2026 to 2027 estimates. This assessment was provided during a Q1 earnings preview for the North American life insurance group, which is a core provider of supplemental health and life insurance products through subsidiaries in the United States and Japan. Management updates indicate that while most of the 2026 guidance remains intact, specific metrics have been clarified following the Q4 2025 earnings call. For operations in Japan, Senior EVP & CFO Max Broden expects underlying earned premiums to decline by 1% to 2%, with an expense ratio projected between 20% and 23%. The benefit ratio is anticipated to range from 60% to 63%, yielding a pretax profit margin of 33% to 36%. In the US market, net earned premium growth is still targeted at the lower end of a 3% to 6% range, with a projected benefit ratio between 48% and 52% and an expense ratio estimated from 36% to 39% as the company expands its newer business lines. The article concludes by noting that despite acknowledging Aflac's investment potential, some analysts view certain AI stocks as offering greater upside with less downside risk, particularly those benefiting from onshoring trends. The text directs readers to a free report regarding undervalued AI stocks influenced by tariff policies but notes that this opinion section is part of the broader coverage surrounding the stock rather than the core financial recommendation update itself.